NORTH CHICAGO, Ill., May 19, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology (ASCO) Annual Meeting (June 4-8) and the virtual European Hematology Association (EHA) congress (June 9-17).
"We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment," said Mohamed Zaki, M.D., Ph.D., vice president and global head of oncology development, AbbVie. "We look forward to showcasing research from our expanding oncology portfolio at the ASCO 2021 annual meeting and EHA 2021 congress."
Presentations include nine oral presentations (two at ASCO and seven at EHA) and 32 poster presentations (13 at ASCO and 19 at EHA).
At ASCO, AbbVie will present data from its Phase 2 CAPTIVATE study evaluating complete response (CR) and progression-free survival (PFS) among other study metrics in previously untreated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) who received an ibrutinib (IMBRUVICA®) + venetoclax (VENCLEXTA®/VENCLYXTO®) combination regimen.
In addition, during the congresses, AbbVie will present results from several studies, including those that evaluate venetoclax in several combination regimens and in multiple hematological malignancies. These include a four-year follow-up of the CLL14 trial of venetoclax plus obinutuzumab in patients with previously untreated CLL, long-term results from the MURANO trial of venetoclax plus rituximab in relapsed/refractory CLL, and additional post-hoc analyses of the VIALE-A trial of venetoclax in combination with azacitidine in patients with acute myeloid leukemia (AML). An up-to seven-year follow up of the ibrutinib RESONATE-2 study in first-line CLL will also be presented and add to robust long-term efficacy and safety data for this therapy.
Details about presentations are as follows:
ASCO 2021 Abstracts |
|
Abstract |
Presentation Details All Times in CT |
Ibrutinib |
|
Up to Seven Years of Follow-up in the |
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Friday, June 4 8:00 a.m. (CT) Poster Discussion |
Phase 1/2 Study of Cirmtuzumab and |
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Friday, June 4 8:00 a.m. (CT) Poster Discussion |
Randomized, Double-blind, Placebo- |
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Friday, June 4 8:00 a.m. (CT) Poster |
Fixed-Duration (FD) First-line Treatment (tx) |
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Monday, June 7 10:30 a.m. to 1:30 p.m. (CT) Oral Presentation |
Venetoclax |
|
Measurable Residual Disease Response in |
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Friday, June 4 8:00 (CT) Poster |
Venetoclax and Azacitidine Combination in |
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Friday, June 4 8:00 (CT) Poster |
Phase 3 VERONA Study of Venetoclax with
|
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Friday, June 4 8:00 a.m. (CT) Poster |
Comparison of Dose Modification Strategies |
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant Friday, June 4 8:00 a.m. (CT) Poster |
Randomized, Phase III Study of Early |
Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia Friday, June 4 8:00 a.m. (CT) Poster
|
Polatuzumab Vedotin + Obinutuzumab + |
Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia Friday, June 4 8:00 a.m. (CT) Poster |
Epcoritamab* |
|
Subcutaneous Epcoritamab in Patients With |
Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia Friday, June 4 8:00 a.m. (CT) Poster |
Phase 3 Trial (GCT3013-05) of Epcoritamab |
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Friday, June 4 8:00 a.m. (CT) Poster |
ABBV-155 |
|
A First-in-Human Study of Mirzotamab |
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Friday, June 4 8:00 a.m. (CT) Poster |
ABBV-184 |
|
Phase 1 First-in-human Study of ABBV-184 |
Session: Developmental Therapeutics—Immunotherapy Friday, June 4 8:00 a.m. (CT) Poster |
The ASCO 2021 Annual Meeting abstracts are available at: https://meetings.asco.org/am/abstracts
* Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' broad oncology collaboration.
EHA 2021 Abstracts |
|
Abstract |
Presentation Details All Times in CEST |
Ibrutinib |
|
Ibrutinib vs Placebo in Combination with |
Session: Stem Cell Transplantation - cGVHD Friday, June 11 9:00 a.m. (CEST) Oral Presentation |
Primary Analysis of the Fixed-Duration Cohort |
Session: Clinical Trials with Targeted Therapies in CLL Friday, June 11 9:00 a.m. (CEST) Oral Presentation |
Real-World Application of National |
Session: Chronic Lymphocytic Leukemia and Related-Disorders – Clinical Friday, June 11 Session: 9:00 a.m. (CEST) Poster |
Effectiveness and Safety of Ibrutinib in Chronic |
Session: Chronic Lymphocytic Leukemia and Related-Disorders – Clinical Friday, June 11 Session: 9:00 a.m. (CEST) Poster |
Ibrutinib, Bendamustine, Rituximab for |
Session: Aggressive Non-Hodgkin Lymphoma – Clinical Friday, June 11 Session: 9:00 a.m. (CEST) Poster |
Ibrutinib Treatment in the First-Line Setting for |
Session: Chronic Lymphocytic Leukemia and Related-Disorders – Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Ibrutinib Plus Rituximab (IR) vs Placebo Plus |
Session: Indolent and Mantle-Cell Non-Hodgkins Lymphoma – Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Preliminary Clinical Data from a Phase 1B |
Session: Indolent and Mantle-cell Non-Hodgkin Lymphoma - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Role of Maintenance Rituximab (MR) After |
Session: Indolent and Mantle-Cell Non-Hodgkins Lymphoma – Clinical 9:00 (CEST) Poster |
Real-World Treatment Patterns and Outcomes |
Session: Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friday, June 11 9:00 (CEST) Poster |
Venetoclax |
|
Efficacy and Safety of Venetoclax in |
Session: Developments in AML therapy Friday, June 11 9:00 a.m. (CEST) Oral Presentation |
Measurable Residual Disease Response in |
Session: Developments in AML therapy Friday, June 11 9:00 a.m. (CEST) Oral Presentation |
Venetoclax-Obinutuzumab for Previously |
Session: Clinical Trials with Targeted Therapies in CLL Friday, June 11 9:00 a.m. (CEST) Oral Presentation |
Genetic Markers and Outcome in Front Line Obinutuzumab Plus Chlorambucil or Venetoclax - Updated Analysis of the CLL14 |
Session: New Biological and Translational Insights in CLL Friday, June 11 9:00 a.m. (CEST) Oral Presentation |
Primary Analysis of the Fixed-Duration Cohort |
Session: Chronic Lymphoid Malignancies Friday, June 11 9:00 a.m. (CEST) Oral Presentation |
French Venetoclax Observational Study |
Session: Chronic lymphocytic leukemia and related disorders – Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Safety and Effectiveness of Venetoclax in |
Session: Chronic Lymphocytic Leukemia and Related-Disorders -- Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Updated Safety and Efficacy of Venetoclax in |
Session: Myelodysplastic Syndromes - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Comparison of Dose Modification Strategies to |
Session: Myelodysplastic Syndromes - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Venetoclax and Azacitidine Combination in |
Session: Myelodysplastic syndromes - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Relationship Between Venetoclax Exposure |
Session: Acute Myeloid Leukemia - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Venetoclax-Obinutuzumab Modulates Clonal |
Session: Chronic Lymphocytic Leukemia and Related Disorders - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Impact of Unfavorable Genetics on Minimal |
Session: Chronic lymphocytic leukemia and Related Disorders - Biology & Translational Research Friday, June 11 9:00 a.m. (CEST) Poster |
Assessing Time to Deterioration in HRQoL in |
Session: Myeloma and Other Monoclonal Gammopathies – Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Cytopenia Management in the Phase 3 VIALE- |
Session: Acute Myeloid Leukemia - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
Real World Treatment Patterns and Clinical |
Acute Myeloid Leukemia - Clinical Abstract publication only |
A Retrospective Analysis of Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia |
Chronic Lymphocytic Leukemia and Related-Disorders - Clinical Abstract publication only |
Navitoclax |
|
Navitoclax and Ruxolitinib for Patients with |
Session: Myeloproliferative Neoplasms - Clinical Friday, June 11 9:00 a.m. (CEST) Poster |
The EHA 2021 Congress abstracts are available at: https://ehaweb.org/congress/eha-congress-2021/abstracts-and-awards/abstract-submission/abstracts-online/
About Ibrutinib (IMBRUVICA®)
IMBRUVICA (ibrutinib) is a once-daily, first-in-class BTK inhibitor that is administered orally, and is jointly developed and commercialized by Pharmacyclics, LLC, an AbbVie Company, and Janssen Biotech, Inc. (Janssen). The BTK protein sends important signals that tell B cells to mature and produce antibodies. BTK signaling is needed by specific cancer cells to multiply and spread.1,2 By blocking BTK, IMBRUVICA may help move abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs.3
Since its launch in 2013, IMBRUVICA® has received 11 FDA approvals across six disease areas: chronic lymphocytic leukemia (CLL) with or without 17p deletion (del17p); small lymphocytic lymphoma (SLL) with or without del17p; Waldenström macroglobulinemia; previously-treated patients with mantle cell lymphoma (MCL)*; previously-treated patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy* – and previously-treated patients with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.4
IMBRUVICA® is now approved in 101 countries and has been used to treat more than 200,000 patients worldwide across its approved indications. IMBRUVICA® is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA® has been granted four Breakthrough Therapy Designations from the U.S. FDA. This designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases. IMBRUVICA® was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway.
Since 2019, the National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education, recommends ibrutinib (IMBRUVICA®) as a preferred regimen for the initial treatment of CLL/SLL and has Category 1 treatment status for treatment-naïve patients without deletion 17p. In January 2020, the NCCN Guidelines® were updated to elevate IMBRUVICA® with or without rituximab from other recommended regimens to a preferred regimen for the treatment of relapsed/refractory MCL, regardless of duration of response to prior chemoimmunotherapy. As of September 2020, the NCCN guidelines were updated to reflect IMBRUVICA® with or without rituximab as the only Category 1 preferred regimen for both untreated and previously treated WM patients.
IMBRUVICA® is being studied alone and in combination with other treatments in several blood and solid tumor cancers and other serious illnesses. IMBRUVICA® is the most comprehensively studied BTK inhibitor, with more than 150 ongoing clinical trials. There are approximately 30 ongoing company-sponsored trials, 14 of which are in Phase 3, and more than 100 investigator-sponsored trials and external collaborations that are active around the world. For more information, visit www.IMBRUVICA.com.
*Accelerated approval was granted for the MCL and MZL indications based on overall response rate. Continued approval for MCL and MZL may be contingent upon verification and description of clinical benefit in confirmatory trials.
Important Side Effect Information5
Before taking IMBRUVICA®, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA® with certain other medicines may affect how IMBRUVICA® works and can cause side effects.
How should I take IMBRUVICA®?
What should I avoid while taking IMBRUVICA®?
What are the possible side effects of IMBRUVICA®?
IMBRUVICA® may cause serious side effects, including:
The most common side effects of IMBRUVICA® in adults with B-cell malignancies (MCL, CLL/SLL, WM and MZL) include:
The most common side effects of IMBRUVICA® in adults with cGVHD include:
Diarrhea is a common side effect in people who take IMBRUVICA®. Drink plenty of fluids during treatment with IMBRUVICA® to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.
These are not all the possible side effects of IMBRUVICA®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of IMBRUVICA®
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use IMBRUVICA® for a condition for which it was not prescribed. Do not give IMBRUVICA® to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about IMBRUVICA® that is written for health professionals.
Please click here for full Prescribing Information.
About VENCLEXTA®/VENCLYXTO® (venetoclax)
VENCLEXTA®/VENCLYXTO® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLXEXTA/VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.
VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood cancers. Venetoclax is approved in more than 80 countries, including the U.S.
Important Safety Information
What is the most important information I should know about VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and may lead to death. Your healthcare provider will do tests to check your risk of getting TLS before you start taking VENCLEXTA. You will receive other medicines before starting and during treatment with VENCLEXTA to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check for TLS when you first start treatment and during treatment with VENCLEXTA. It is important to keep your appointments for blood tests. Tell your healthcare provider right away if you have any symptoms of TLS during treatment with VENCLEXTA, including fever, chills, nausea, vomiting, confusion, shortness of breath, seizures, irregular heartbeat, dark or cloudy urine, unusual tiredness, or muscle or joint pain.
Drink plenty of water during treatment with VENCLEXTA to help reduce your risk of getting TLS.
Drink 6 to 8 glasses (about 56 ounces total) of water each day, starting 2 days before your first dose, on the day of your first dose of VENCLEXTA, and each time your dose is increased.
Your healthcare provider may delay, decrease your dose, or stop treatment with VENCLEXTA if you have side effects. When restarting VENCLEXTA after stopping for 1 week or longer, your healthcare provider may again check for your risk of TLS and change your dose.
Who should not take VENCLEXTA?
Certain medicines must not be taken when you first start taking VENCLEXTA and while your dose is being slowly increased because of the risk of increased TLS.
Before taking VENCLEXTA, tell your healthcare provider about all of your medical conditions,
including if you:
What should I avoid while taking VENCLEXTA?
You should not drink grapefruit juice or eat grapefruit, Seville oranges (often used in marmalades), or starfruit while you are taking VENCLEXTA. These products may increase the amount of VENCLEXTA in your blood.
What are the possible side effects of VENCLEXTA?
VENCLEXTA can cause serious side effects, including:
Tell your healthcare provider right away if you have a fever or any signs of an infection during treatment with VENCLEXTA.
The most common side effects of VENCLEXTA when used in combination with obinutuzumab or rituximab or alone in people with CLL or SLL include low white blood cell counts; low platelet counts; low red blood cell counts; diarrhea; nausea; upper respiratory tract infection; cough; muscle and joint pain; tiredness; and swelling of your arms, legs, hands, and feet.
The most common side effects of VENCLEXTA in combination with azacitidine or decitabine or low-dose cytarabine in people with AML include nausea; diarrhea; low platelet count; constipation; low white blood cell count; fever with low white blood cell count; tiredness; vomiting; swelling of arms, legs, hands, or feet; fever; infection in lungs; shortness of breath; bleeding; low red blood cell count; rash; stomach (abdominal) pain; infection in your blood; muscle and joint pain; dizziness; cough; sore throat; and low blood pressure.
VENCLEXTA may cause fertility problems in males. This may affect your ability to father a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of VENCLEXTA. Call your doctor for medical advice about side effects.
You are encouraged to report side effects of prescription drug to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
If you cannot afford your medication, contact genentech-access.com/patient/brands/venclexta for assistance.
The full U.S. prescribing information, including Medication Guide, for VENCLEXTA® can be found here.
Indication and Important VENCLYXTO® (venetoclax) EU Safety Information7
Indication
Venclyxto® in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
Venclyxto® in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.
Venclyxto® monotherapy is indicated for the treatment of CLL:
Contraindications
Hypersensitivity to the active substance or to any of the excipients is contraindicated. Concomitant use of strong CYP3A inhibitors at initiation and during the dose-titration phase due to increased risk for tumor lysis syndrome (TLS). Concomitant use of preparations containing St. John's wort as VENCLYXTO® efficacy may be reduced.
Special Warnings & Precautions for Use
TLS, including fatal events, has occurred in patients with previously treated CLL with high tumour burden when treated with VENCLYXTO®. VENCLYXTO® poses a risk for TLS in the initial 5-week dose-titration phase. Changes in electrolytes consistent with TLS that require prompt management can occur as early as 6 to 8 hours following the first dose of VENCLYXTO® and at each dose increase. Patients should be assessed for risk and should receive appropriate prophylaxis, monitoring, and management for TLS.
Neutropenia (grade 3 or 4) has been reported and complete blood counts should be monitored throughout the treatment period.
Serious infections including sepsis with fatal outcome have been reported. Monitoring of any signs and symptoms of infection is required. Suspected infections should receive prompt treatment including antimicrobials and dose interruption or reduction as appropriate.
Live vaccines should not be administered during treatment or thereafter until B-cell recovery.
Drug Interactions
CYP3A inhibitors may increase VENCLYXTO® plasma concentrations. At initiation and dose-titration phase: Strong CYP3A inhibitors are contraindicated due to increased risk for TLS and moderate CYP3A inhibitors should be avoided. If moderate CYP3A inhibitors must be used, physicians should refer to the SmPC for dose adjustment recommendations. At steady daily dose: moderate or strong CYP3A inhibitors must be used, physicians should refer to the VENCLYXTO® summary of product characteristics (SmPC) for dose adjustment recommendations.
Avoid concomitant use of P-gp and BCRP inhibitors at initiation and during the dose titration phase.
CYP3A4 inducers may decrease VENCLYXTO® plasma concentrations. Avoid coadministration with strong or moderate CYP3A inducers. These agents may decrease venetoclax plasma concentrations.
Co-administration of bile acid sequestrants with VENCLYXTO® is not recommended as this may reduce the absorption of VENCLYXTO®.
Adverse Reactions
The most commonly occurring adverse reactions (>=20%) of any grade in patients receiving venetoclax in the combination studies with obinutuzumab or rituximab were neutropenia, diarrhoea, and upper respiratory tract infection. In the monotherapy studies, the most common adverse reactions were neutropenia/neutrophil count decreased, diarrhoea, nausea, anaemia, fatigue, and upper respiratory tract infection.
The most frequently occurring serious adverse reactions (>=2%) in patients receiving venetoclax in combination with obinutuzumab or rituximab were pneumonia, sepsis, febrile neutropenia, and TLS. In the monotherapy studies, the most frequently reported serious adverse reactions (>=2%) were pneumonia and febrile neutropenia.
Discontinuations due to adverse reactions occurred in 16% of patients treated with venetoclax in combination with obinutuzumab or rituximab in the CLL14 and Murano studies respectively. In the monotherapy studies with venetoclax, 11% of patients discontinued due to adverse reactions.
Dosage reductions due to adverse reactions occurred in 21% of patients treated with the combination of venetoclax and obinutuzumab in CLL14 and in 15% of patients treated with the combination of venetoclax and in Murano and in 14% of patients treated with venetoclax in the monotherapy studies. The most common adverse reaction that led to dose interruptions was neutropenia.
Specific Populations
Patients with reduced renal function (CrCl <80 mL/min) may require more intensive prophylaxis and monitoring to reduce the risk of TLS. Safety in patients with severe renal impairment (CrCl <30 mL/min) or on dialysis has not been established, and a recommended dose for these patients has not been determined.
For patients with severe (Child-Pugh C) hepatic impairment, a dose reduction of at least 50% throughout treatment is recommended.
VENCLYXTO® may cause embryo-fetal harm when administered to a pregnant woman. Advise nursing women to discontinue breastfeeding during treatment.
This is not a complete summary of all safety information. See VENCLYXTO® full summary of product characteristics (SmPC) at https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Globally, prescribing information varies; refer to the individual country product label for complete information.
About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for multiple blood cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
REFERENCES
1 Genetics Home Reference. Isolated growth hormone deficiency. ?http://ghr.nlm.nih.gov/condition/isolated-growth-hormone-deficiency. Accessed?November 2020.
2 Turetsky, et al. Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor. Scientific Reports. volume 4, Article number: 4782 (2014)
3 de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119(11):2590-2594.
4 IMBRUVICA U.S. Prescribing Information,?April 2020.
5 IMBRUVICA U.S. Prescribing Information,?April 2020.
6 VENCLEXTA (venetoclax) [Package Insert].?North Chicago, IL.: AbbVie Inc.
7 Summary of Product Characteristics for VENCLYXTO (venetoclax). Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG.
SOURCE AbbVie
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?